We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+29.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.47B
AUM Growth
+$451M
(+5%)
Cap. Flow
+$1.13B
Cap. Flow
% of AUM
11.96%
Top 10 Holdings %
Top 10 Hldgs %
21.59%
Holding
903
New
107
Increased
255
Reduced
393
Closed
103
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$51.9M |
| 2 |
Merck
MRK
|
+$50.9M |
| 3 |
Danaher
DHR
|
+$45.3M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$37.8M |
| 5 |
JD.com
JD
|
+$37.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$103M |
| 2 |
Alibaba
BABA
|
+$98.6M |
| 3 |
Salesforce
CRM
|
+$62.5M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$59.4M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$48.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.61% |
| 2 | Technology | 20.94% |
| 3 | Consumer Discretionary | 8.9% |
| 4 | Financials | 8.59% |
| 5 | Communication Services | 7.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Oneok
OKE
$55.9B
| $7.9M | 0.08% |
132,714
-679
| -0.5% | -$22.1K |
|
252
Ralph Lauren
RL
$22.5B
| $7.88M | 0.08% |
+37,033
| New | +$2.72M |
|
253
State Street
STT
$50.2B
| $7.88M | 0.08% |
123,973
+79,947
| +182% | +$4.83M |
|
254
SBA Communications
SBAC
$18.6B
| $7.85M | 0.08% |
26,360
+15,128
| +135% | +$4.47M |
|
255
EPAM Systems
EPAM
$5.25B
| $7.76M | 0.08% |
+30,800
| New | +$6.78M |
|
256
Trex
TREX
$4.57B
| $7.75M | 0.08% |
119,236
+44,752
| +60% | +$2.39M |
|
257
Eversource Energy
ES
$28.4B
| $7.63M | 0.08% |
91,589
-48,093
| -34% | -$3.98M |
|
258
SLB Ltd
SLB
$74.2B
| $7.59M | 0.08% |
412,500
+74,532
| +22% | +$1.31M |
|
259
Prudential Financial
PRU
$43B
| $7.54M | 0.08% |
123,837
+2,951
| +2% | +$173K |
|
260
Verisk Analytics
VRSK
$27.8B
| $7.54M | 0.08% |
44,291
+32,358
| +271% | +$5.11M |
|
261
Monster Beverage
MNST
$95.6B
| $7.36M | 0.08% |
212,434
-72,642
| -25% | -$2.37M |
|
262
Deere & Co
DE
$173B
| $7.33M | 0.08% |
46,662
+5,729
| +14% | +$830K |
|
263
Nektar Therapeutics
NKTR
$2.39B
| $7.32M | 0.08% |
21,062
-4,671
| -18% | -$1.46M |
|
264
Fidelity National Information Services
FIS
$23.2B
| $7.28M | 0.08% |
54,249
-4,849
| -8% | -$637K |
|
|
PVLA
265
Palvella Therapeutics
PVLA
$2.05B
| $7.27M | 0.08% |
29,318
+10,716
| +58% | +$2.51M |
|
266
Enphase Energy
ENPH
$4.79B
| $7.26M | 0.08% |
152,644
+32,425
| +27% | +$1.55M |
|
267
Itron
ITRI
$4.75B
| $7.21M | 0.08% |
108,774
+57,189
| +111% | +$3.64M |
|
268
Gen Digital
GEN
$16.5B
| $7.2M | 0.08% |
363,219
+239,622
| +194% | +$4.88M |
|
269
HP
HPQ
$25.9B
| $7.18M | 0.08% |
411,908
+249,912
| +154% | +$3.97M |
|
|
YMAB
270
DELISTED
Y-mAbs Therapeutics
YMAB
| $7.13M | 0.08% |
164,997
+107,451
| +187% | +$4.06M |
|
271
Old Dominion Freight Line
ODFL
$47.1B
| $7.09M | 0.07% |
83,558
+73,126
| +701% | +$5.55M |
|
272
Caterpillar
CAT
$387B
| $7.08M | 0.07% |
55,987
-27,170
| -33% | -$3.22M |
|
273
West Pharmaceutical
WST
$23.7B
| $7.06M | 0.07% |
+31,096
| New | +$6.11M |
|
274
Cognizant
CTSH
$23.8B
| $6.95M | 0.07% |
122,347
+77,291
| +172% | +$4.15M |
|
275
Principal Financial Group
PFG
$24.5B
| $6.91M | 0.07% |
166,365
+93,041
| +127% | +$3.39M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2020 Portfolio in Review
As of Q2 2020, Candriam SCA held 903 positions worth $9.47B, up 5% from $9.02B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $1.13B of net new capital in Q2 2020, opening 107 new positions and adding to 255 existing holdings. Its largest new stake was JD.com: 744,410 shares worth $44.8M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $103M trimmed.
- Candriam SCA's largest Q2 2020 buy was JD.com: 744,410 shares worth $44.8M.
- Candriam SCA added most to Blueprint Medicines in Q2 2020, an estimated $51.9M increase.
- Candriam SCA's biggest Q2 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $103M.
- Candriam SCA fully exited Salesforce in Q2 2020, selling an estimated $62.5M.
- Candriam SCA's ten largest holdings make up 22% of its $9.47B portfolio in Q2 2020.
- Candriam SCA opened 107 new positions and closed 103 in Q2 2020.
- Candriam SCA's portfolio value rose 5% quarter-over-quarter to $9.47B.
Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.